Colorectal Cancer MMR Testing - FOI Response Register

1. Which nation is the Health and Social Care Trust or Health Board that you are answering this FOI request on behalf of in?

Scotland

2. Which Health and Social Care Trust or Health Board are you answering this FOI request on behalf of?

NHS Shetland

3. Do you use NICE guidelines to inform measures related to a Lynch Syndrome Clinical Pathway? If you use another set of relevant national guidelines, please specify this in the 'Other' box.

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested as this service is provided to Shetland patients by NHS Grampian.

An FOI request to NHS Grampian can be submitted at the following address: gram.foi@nhs.scot

4. Do you offer newly diagnosed bowel cancer patients in your health authority a test for molecular features of Lynch syndrome e.g., using either immunohistochemistry or microsatellite instability testing?

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested as this service is provided to Shetland patients by NHS Grampian.

5. If such testing is offered, over the last financial year what proportion of newly diagnosed patients have had a test carried out for the molecular features of Lynch Syndrome? Please enter N/A if such testing is not available.

N/A

6. If such testing measures are in place, at what stage is it aimed that this testing takes place?

N/A

7. What are the main barriers you face to introducing testing for molecular features of Lynch syndrome in all newly diagnosed bowel cancer patients? Please select all that apply, and where possible specify why in the following free text box.

N/A

8. Where possible, please use the below free text box to explain why the above barriers present difficulty to your health authority in introducing testing for molecular features of Lynch syndrome in all newly diagnosed bowel cancer patients.

N/A

9. At what point in the clinical pathway are the above barriers having the greatest effect with regards to being able to adhere to NICE or relevant national guidelines associated with Lynch Syndrome? 

N/A

10. Do you audit diagnostic outcomes within your health authority to ensure that patients are being tested for molecular features for Lynch syndrome? 

N/A

11. Is this test carried out as a reflex test i.e., automatically or upon referral?

N/A

12. Is there a named individual within each colorectal team in your health authority who is responsible for ensuring testing for molecular features of Lynch syndrome take place?

N/A

13. What wraparound care measures are in place for those that are confirmed to have Lynch Syndrome? Please select all that apply.

N/A

14. Upon identification of individuals with Lynch Syndrome, do you suggest that you provide letters for at risk family members to take to their GP that highlight their risk of Lynch Syndrome and request referral to genomic services for germline testing?

N/A

15. Over the last financial year, what proportion of close relatives of individuals identified to have Lynch Syndrome have been tested for Lynch Syndrome?

N/A

16. Upon identification of individuals with Lynch Syndrome who do not currently have cancer, is regular colonoscopic surveillance provided?

N/A

17. Over the last financial year, what proportion of individuals identified to have Lynch Syndrome who are offered regular colonoscopic surveillance are provided regular colonoscopies within the timelines selected above?

N/A

18. If such surveillance is offered how are patients called and recalled for these tests? Please enter N/A if you do not offer such surveillance.

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested as this service is provided to Shetland patients by NHS Grampian.